EP2775835A4 - METHODS FOR TREATING GOUT IN GROUPS OF PATIENTS - Google Patents

METHODS FOR TREATING GOUT IN GROUPS OF PATIENTS

Info

Publication number
EP2775835A4
EP2775835A4 EP11875027.2A EP11875027A EP2775835A4 EP 2775835 A4 EP2775835 A4 EP 2775835A4 EP 11875027 A EP11875027 A EP 11875027A EP 2775835 A4 EP2775835 A4 EP 2775835A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating gout
patient subpopulations
subpopulations
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11875027.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2775835A1 (en
Inventor
Gopal Chandra Saha
Brian K Roberts
Brian Edward Lavan
Charles A Mcwherter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatex Inc
CymaBay Therapeutics Inc
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Publication of EP2775835A1 publication Critical patent/EP2775835A1/en
Publication of EP2775835A4 publication Critical patent/EP2775835A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11875027.2A 2011-11-04 2011-11-04 METHODS FOR TREATING GOUT IN GROUPS OF PATIENTS Withdrawn EP2775835A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (2)

Publication Number Publication Date
EP2775835A1 EP2775835A1 (en) 2014-09-17
EP2775835A4 true EP2775835A4 (en) 2015-07-29

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11875027.2A Withdrawn EP2775835A4 (en) 2011-11-04 2011-11-04 METHODS FOR TREATING GOUT IN GROUPS OF PATIENTS

Country Status (14)

Country Link
EP (1) EP2775835A4 (OSRAM)
JP (1) JP6047172B2 (OSRAM)
KR (1) KR101848122B1 (OSRAM)
CN (1) CN104066323A (OSRAM)
AU (1) AU2011380509B2 (OSRAM)
BR (1) BR112014010693A2 (OSRAM)
CA (1) CA2859689C (OSRAM)
CL (1) CL2014001156A1 (OSRAM)
IL (1) IL232385A (OSRAM)
MX (1) MX354846B (OSRAM)
NZ (1) NZ624714A (OSRAM)
SG (1) SG11201402027PA (OSRAM)
WO (1) WO2013066352A1 (OSRAM)
ZA (1) ZA201403574B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (en) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc METHOD FOR THE TREATMENT OF HYPERURICEMIA IN PATIENTS WITH A GOG THROUGH HALOFENATE OR HALOFENIC ACID AND AN INFLAMMATORY INHIBITOR
CN104068288B (zh) * 2014-07-25 2016-08-24 许伟琦 一种防尿路结石的饲料添加剂
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103058944B (zh) * 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US6613802B1 (en) * 1999-06-04 2003-09-02 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer", 20 October 2011 (2011-10-20), XP002740530, Retrieved from the Internet <URL:http://www.fiercebiotech.com> [retrieved on 20150603] *
ANONYMOUS: "Metabolex Initiates Phase 2 Trial of Arhalofenate", 19 May 2011 (2011-05-19), XP002740529, Retrieved from the Internet <URL:http://www.prnewswire.com/news-releases> [retrieved on 20150603] *
EDWARDS K D G ET AL: "AMINO NUCLEOSIDE INDUCED CHRONIC RENAL FAILURE IN RATS ENHANCEMENT BY DIETARY HYPER LIPIDEMIAS AND PROTECTION BY A HYPO LIPIDEMIC DIET OR HALOFENATE", KIDNEY INTERNATIONAL, vol. 14, no. 6, 1978, pages 723, XP002740532, ISSN: 0085-2538 *
EDWARDS K D G ET AL: "PROTECTION BY L TRYPTOPHAN OR HALOFENATE AGAINST HYPER LIPIDEMIA AND ACUTE OR CHRONIC AMINO NUCLEOSIDE NEPHROSIS IN SUCROSE LARD FED RATS", KIDNEY INTERNATIONAL, vol. 12, no. 6, 1977, pages 480, XP002740533, ISSN: 0085-2538 *
EL-ZAWAWY HOSSAM ET AL: "Managing gout: How is it different in patients with chronic kidney disease?", CLEVELAND CLINIC JOURNAL OF MEDICINE, vol. 77, no. 12, December 2010 (2010-12-01), pages 919 - 928, XP002740531 *
MAHESH J FULDEORE ET AL: "Chronic kidney disease in gout in a managed care setting", BMC NEPHROLOGY, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 3 August 2011 (2011-08-03), pages 36, XP021108842, ISSN: 1471-2369, DOI: 10.1186/1471-2369-12-36 *
See also references of WO2013066352A1 *

Also Published As

Publication number Publication date
EP2775835A1 (en) 2014-09-17
CN104066323A (zh) 2014-09-24
IL232385A (en) 2017-10-31
IL232385A0 (en) 2014-06-30
MX354846B (es) 2018-03-22
NZ624714A (en) 2016-01-29
CA2859689A1 (en) 2013-05-10
BR112014010693A2 (pt) 2020-11-10
CL2014001156A1 (es) 2015-01-16
ZA201403574B (en) 2015-11-25
KR101848122B1 (ko) 2018-04-11
JP6047172B2 (ja) 2016-12-21
KR20140123927A (ko) 2014-10-23
MX2014005399A (es) 2015-04-08
WO2013066352A1 (en) 2013-05-10
AU2011380509A1 (en) 2014-05-29
CA2859689C (en) 2018-05-22
SG11201402027PA (en) 2014-09-26
JP2014532759A (ja) 2014-12-08
AU2011380509B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
HUE045988T2 (hu) Csúsztatható berendezés hõterápiás kezeléshez
PL3412687T3 (pl) Sposoby leczenia dlbcl
EP2531625A4 (en) PROCESS FOR PROCESSING FRACTURE MATERIALS
ZA201208219B (en) Method for treating wasterwater
LT2735250T (lt) Slankiojančio tipo aparatas, skirtas termoterapiniam gydymui
IL220594A0 (en) Treatment method
SG11201401981TA (en) Methods for treating gout flares
ZA201403574B (en) Methods for treating gout in patient subpopulations
ZA201308117B (en) Avian-based treatment
IL228744A0 (en) A method for treating diseases related to interferon alpha
GB201105523D0 (en) Treatment method
GB201121950D0 (en) Treatment process
EP2813798A4 (en) METHOD OF EXPLOSION TREATMENT
SG11201402309YA (en) Process for medical components and uses thereof
GB201102283D0 (en) Treatment
EP2768536A4 (en) METHOD OF TREATING TYPE I AND TYPE II DIABETES
GB201109796D0 (en) Treatment device
SG11201403180YA (en) Improvements in machining apparatus
GB201102270D0 (en) Treatment
GB201102276D0 (en) Treatment
GB201102271D0 (en) Treatment
GB201102268D0 (en) Treatment
GB201111247D0 (en) Treatment
GB201109119D0 (en) Treatment
GB201102263D0 (en) Treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 37/00 20060101ALI20150609BHEP

Ipc: A61P 19/06 20060101ALI20150609BHEP

Ipc: A61K 31/20 20060101AFI20150609BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150626

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYMABAY THERAPEUTICS, INC.

17Q First examination report despatched

Effective date: 20170331

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYMABAY THERAPEUTICS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIATEX, INC.

Owner name: CYMABAY THERAPEUTICS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190205